Last reviewed · How we verify

Placebo Corifollitropin alfa

Organon and Co · Phase 3 active Small molecule

Placebo Corifollitropin alfa is a Gonadotropin; long-acting FSH analog Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Controlled ovarian hyperstimulation in women undergoing assisted reproductive technology (ART) for infertility.

Corifollitropin alfa is a long-acting follicle-stimulating hormone (FSH) analog that stimulates ovarian follicle development for assisted reproductive technology.

Corifollitropin alfa is a long-acting follicle-stimulating hormone (FSH) analog that stimulates ovarian follicle development for assisted reproductive technology. Used for Controlled ovarian hyperstimulation in women undergoing assisted reproductive technology (ART) for infertility.

At a glance

Generic namePlacebo Corifollitropin alfa
SponsorOrganon and Co
Drug classGonadotropin; long-acting FSH analog
TargetFSH receptor (FSHR)
ModalitySmall molecule
Therapeutic areaReproductive/Fertility
PhasePhase 3

Mechanism of action

Corifollitropin alfa is a recombinant FSH variant with an extended half-life due to fusion with the beta subunit of human chorionic gonadotropin (hCG). It binds to FSH receptors on ovarian granulosa cells to promote follicle growth and estrogen production during controlled ovarian hyperstimulation in fertility treatment. The extended half-life allows for less frequent dosing compared to conventional FSH preparations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo Corifollitropin alfa

What is Placebo Corifollitropin alfa?

Placebo Corifollitropin alfa is a Gonadotropin; long-acting FSH analog drug developed by Organon and Co, indicated for Controlled ovarian hyperstimulation in women undergoing assisted reproductive technology (ART) for infertility.

How does Placebo Corifollitropin alfa work?

Corifollitropin alfa is a long-acting follicle-stimulating hormone (FSH) analog that stimulates ovarian follicle development for assisted reproductive technology.

What is Placebo Corifollitropin alfa used for?

Placebo Corifollitropin alfa is indicated for Controlled ovarian hyperstimulation in women undergoing assisted reproductive technology (ART) for infertility.

Who makes Placebo Corifollitropin alfa?

Placebo Corifollitropin alfa is developed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).

What drug class is Placebo Corifollitropin alfa in?

Placebo Corifollitropin alfa belongs to the Gonadotropin; long-acting FSH analog class. See all Gonadotropin; long-acting FSH analog drugs at /class/gonadotropin-long-acting-fsh-analog.

What development phase is Placebo Corifollitropin alfa in?

Placebo Corifollitropin alfa is in Phase 3.

What are the side effects of Placebo Corifollitropin alfa?

Common side effects of Placebo Corifollitropin alfa include Ovarian hyperstimulation syndrome (OHSS), Headache, Injection site reactions, Abdominal pain/discomfort, Nausea.

What does Placebo Corifollitropin alfa target?

Placebo Corifollitropin alfa targets FSH receptor (FSHR) and is a Gonadotropin; long-acting FSH analog.

Related